MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2016 International Congress

    Detailed evaluation of dyskinesias using multiple endpoints in a randomized, placebo-controlled trial of Parkinson’s disease patients with motor fluctuations

    C. Kenney, K. Kieburtz, W. Olanow, S. Bandak (San Francisco, CA, USA)

    Objective: To analyze all dyskinesia data from a Phase 2b trial of fluctuating Parkinson patients in order to understand the overall impact a study drug…
  • 2016 International Congress

    Construction of a levodopa-response index from wearable sensors for quantifying Parkinson’s disease motor functions: Preliminary results

    M. Memedi, D. Nyholm, J. Westin, M. Senek, A. Medvedev, H. Askmark, S.M. Aquilonius, F. Bergquist, R. Constantinescu, F. Ohlsson, J. Spira, S. Lycke, A. Ericsson (Falun, Sweden)

    Objective: The goal of the study is to investigate whether wrist worn motion sensors are feasible tools to measure motor functions in Parkinson's disease (PD).…
  • 2016 International Congress

    Intrastriatal injection of ionomycin profoundly changes motor response to L-DOPA and its underlying molecular mechanisms

    C. Han, S. Nie, G. Chen, K. Ma, N. Xiong, Z. Zhang, Y. Xu, T. Wang, S.M. Papa, X. Cao (Wuhan, People's Republic of China)

    Objective: We investigated whether intrastriatal injection of ionomycin to hemiParkinsonian rats produced changes in L-DOPA responses including LID and analyzed the effects of ionomycin on…
  • 2016 International Congress

    Are clinical certainty ratings helpful in the diagnosis of Parkinson’s disease?

    H.V. Gupta, S.H. Mehta, J.G. Hentz, H.A. Shill, E. Driver-Dunckley, M.N. Sabbagh, C.M. Belden, B.N. Dugger, T.G. Beach, G.E. Serrano, L.I. Sue, C.H. Adler (Scottsdale, AZ, USA)

    Objective: To determine whether clinical certainty ratings are helpful in predicting pathologically proven PD. Background: Clinical diagnostic criteria for PD rely on rest tremor, bradykinesia,…
  • 2016 International Congress

    Objective movement recording in PD patient before and after STN-DBS

    D. Flisar, B. Pikš, B. Meglic, Z. Pirtošek, G. Kramberger (Ljubljana, Slovenia)

    Objective: Case study: objective recording of motor fluctuations and dyskinesia in PD patient before and after STN-DBS by using continuous accelerometry system and automated computer…
  • 2016 International Congress

    Age associated effects of levodopa administration on striatal acetylcholinesterase activity

    M. Messripour, A. Mesripour (Isfahan, Islamic Republic of Iran)

    Objective: The aim of this study was to compare short- and long-term effects of levodopa on acetylcholinesterase activity in young and old rat brain striatum.…
  • 2016 International Congress

    ADCY5 screening in paediatric-onset hyperkinetic movement disorders: Report of three new Italian families

    M. Carecchio, N.E. Mencacci, G. Zorzi, F. Zibordi, C. Fusco, A. Iodice, L. Veneziano, C. Barzaghi, L. 'RBibo, N. Wood, B. Garavaglia, N. Nardocci (Milan, Italy)

    Objective: To report three new cases with pathogenic ADCY5 mutations and describe their clinical phenotype. Background: ADCY5 is a recently identified gene responsible for a…
  • 2016 International Congress

    Developing a new home monitoring device for dyskinesia in Parkinson’s disease

    J.E. Alty, J. Cosgrove, M.A. Lones, S. Jamieson, P. Duggan-Carter, C. Peacey, C. Wicks, R.F. Naylor, A.J. Turner, S.L. Smith (Leeds, United Kingdom)

    Objective: To evaluate how accurately a new device can discriminate different clinical severities of dyskinesia from non-dyskinetic movements in patients with Parkinson's disease (PD). Background:…
  • 2016 International Congress

    A comparative study of clinical profile of patients of drug induced parkinsonism with idiopathic Parkinson’s disease

    S. Kushwaha, R. Mistry, A. Anthony, S. Khurana (Delhi, India)

    Objective: Drug induced parkinsonism (DIP), caused by various group of drugs, is second most common etiology of parkinsonism after Idiopathic Parkinson's disease (IPD). No major…
  • 2016 International Congress

    Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia

    G. Gangarossa, M. Guzman, V. Prado, M. Prado, S. Daumas, S. El Mestikawy, E. Valjent (Paris, France)

    Objective: To evaluate the role of the atypical vesicular glutamate transporter 3 (VGLUT3) and the vesicular acetylcholine transporter (VAChT) in L-DOPA-induced dyskinesia. Background: Parkinson's disease…
  • « Previous Page
  • 1
  • …
  • 36
  • 37
  • 38
  • 39
  • 40
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An atypical and interesting feature of Parkinson´s disease
  • #25136 (not found)
  • Unusual prolonged survival in multiple system atrophy: A case report
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley